BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Mystery foot suggests a second early human relative lived alongside Lucy - 2Heading to Florida for NASA's Artemis 2 moon launch? Here's what to know before you go
- 3Lahav 433 head Asst.-Ch. Meni Benjamin named as police officer investigated for breach of trust
- 4Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- 5Why screening for the deadliest cancer in the U.S. misses most cases
- U.S. overhauls childhood vaccine schedule, recommends fewer shots
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Defence chiefs of Thailand and Cambodia to discuss ceasefire
- German hauliers warn soaring energy prices may soon impact consumers
- Most loved Web-based feature: Which Stage Do You Like
- Seoul says sorry after unapproved drone flights into North Korea
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
